IL6 and COVID-19: Of particular interest in this network appeared miR-338-5p (RT-pPCR validated) targeting IL6, a key mediator of the cytokine storm seen in severe cases of COVID-19 (25) and a pharmacologic target of tocilizumab, which may provide a survival benefit in COVID-19 patients (26).